Stay updated on MBG453 Combo in IPSS-R MDS Clinical Trial
Sign up to get notified when there's something new on the MBG453 Combo in IPSS-R MDS Clinical Trial page.

Latest updates to the MBG453 Combo in IPSS-R MDS Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.3%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe web page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.SummaryDifference0.9%
- Check30 days agoChange DetectedNovartis has decided to terminate the sabatolimab clinical development program early due to the failure of Phase II and III studies to meet their primary objectives, although this decision was not based on safety concerns.SummaryDifference6%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check88 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
- Check95 days agoChange DetectedThe website has been updated to version 2.14.2 on January 31, 2025, following the removal of version 2.14.1 on December 12, 2024.SummaryDifference1%
Stay in the know with updates to MBG453 Combo in IPSS-R MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MBG453 Combo in IPSS-R MDS Clinical Trial page.